Mogrify is a biotechnology company that develops proprietary tailored cell conversions that power every cell therapy.
Mogrify has raised €38M across 3 funding rounds from 7 investors, most recently a Series A round in Oct 2023. Based in Cambridge, UK; founded 2016; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors |
|---|
| 2023-10-03 | Series A | €9.6M | Ahren Innovation Capital,Astellas Venture Management,Dr Jonathan Milner,Parkwalk Advisors,Trend Investment Group | View deal → |
| 2021-05-04 | Series A | €14M | 24Haymarket,Astellas Venture Management,Dr Darrin M Disley,Dr Jonathan Milner,Parkwalk Advisors | View deal → |
| 2019-10-01 | Series A | €15M | Ahren Innovation Capital | View deal → |
